Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer

Science Translational Medicine

Volumn 8, Issue 346, 2016, Pages

  Tie, Jeanne ^a,b,c,d   Wang, Yuxuan ^e   Tomasetti, Cristian ^f,g   Li, Lu ^f   Springer, Simeon ^e   Kinde, Isaac ^h   Silliman, Natalie ^e   Tacey, Mark ⁱ   Wong, Hui Li ^a,c,d   Christie, Michael ^a,c   Kosmider, Suzanne ^b   Skinner, Iain ^b   Wong, Rachel ^a,j,k   Steel, Malcolm ^j   Tran, Ben ^a,b,c,d   Desai, Jayesh ^a,c,d   Jones, Ian ^c,d   Haydon, Andrew ^l   Hayes, Theresa ^m   Price, Tim J ⁿ   Strausberg, Robert L ^o   Diaz, Luis A ^e   Papadopoulos, Nickolas ^e   Kinzler, Kenneth W ^e   Vogelstein, Bert ^e   Gibbs, Peter ^a,b,c,d,o   more..

^a WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b WESTERN HEALTH   (Australia)

^c ROYAL MELBOURNE HOSPITAL   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e JOHNS HOPKINS UNIVERSITY   (United States)

^f JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^h PapGene Inc   (United States)

ⁱ UNIVERSITY OF MELBOURNE   (Australia)

^j EASTERN HEALTH   (Australia)

^k MONASH UNIVERSITY   (Australia)

^l ALFRED HOSPITAL   (Australia)

^m Department of General Surgery   (Australia)

ⁿ UNIVERSITY OF ADELAIDE   (Australia)

^o LUDWIG INSTITUTE FOR CANCER RESEARCH   (Australia)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CIRCULATING TUMOR DNA; DNA; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; COLON CANCER; CONTROLLED STUDY; DNA DETERMINATION; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; PATIENT IDENTIFICATION; PREDICTION; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; RECURRENCE RISK; BLOOD; COLON TUMOR; DISEASE FREE SURVIVAL; GENETICS; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; TUMOR RECURRENCE;

CIRCULATING TUMOR DNA; COLONIC NEOPLASMS; DISEASE-FREE SURVIVAL; HUMANS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NEOPLASM, RESIDUAL; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES;

EID: 84978062740     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.aaf6219     Document Type: Article

References (40)

1. J. Ferlay, I. Soerjomataram, R. Dikshit, S. Eser, C. Mathers, M. Rebelo, D. M. Parkin, D. Forman, F. Bray, Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer 136, E359-E386 (2015).
2. S. Edge, D. R. Byrd, C. C. Compton, A. G. Fritz, F. L. Greene, A. Trotti, AJCC Cancer Staging Manual (Springer, New York, 2010), 648 pp.
3. C. E. Dukes, The classification of cancer of the rectum. J. Pathol. Bacteriol. 35, 323-332 (1932).
4. H.-M. Quah, J. F. Chou, M. Gonen, J. Shia, D. Schrag, R. G. Landmann, J. G. Guillem, P. B. Paty, L. K. Temple, W. D. Wong, M. R. Weiser, Identification of patients with high-risk stage II colon cancer for adjuvant therapy. Dis. Colon Rectum 51, 503-507 (2008).
5. D. Niedzwiecki, M. M. Bertagnolli, R. S. Warren, C. C. Compton, N. E. Kemeny, A. B. Benson III, S. G. Eckhardt, S. Alberts, G. N. Porjosh, D. J. Kerr, A. Fields, P. Rougier, J. M. Pipas, J. H. Schwartz, J. Atkins, M. O'Rourke, M. C. Perry, R. M. Goldberg, R. J. Mayer, T. A. Colacchio, Documenting the natural history of patients with resected stage II adenocarcinoma of the colon after random assignment to adjuvant treatment with edrecolomab or observation: Results from CALGB 9581. J. Clin. Oncol. 29, 3146-3152 (2011).
6. C. M. Ribic, D. J. Sargent, M. J. Moore, S. N. Thibodeau, A. J. French, R. M. Goldberg, S. R. Hamilton, P. Laurent-Puig, R. Gryfe, L. E. Shepherd, D. Tu, M. Redston, S. Gallinger, Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N. Engl. J. Med. 349, 247-257 (2003).
7. D. J. Sargent, S. Marsoni, G. Monges, S. N. Thibodeau, R. Labianca, S. R. Hamilton, A. J. French, B. Kabat, N. R. Foster, V. Torri, C. Ribic, A. Grothey, M. Moore, A. Zaniboni, J.-F. Seitz, F. Sinicrope, S. Gallinger, Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J. Clin. Oncol. 28, 3219-3226 (2010).
8. S. Kopetz, J. Tabernero, R. Rosenberg, Z.-Q. Jiang, V. Moreno, T. Bachleitner-Hofmann, G. Lanza, L. Stork-Sloots, D. Maru, I. Simon, G. Capellà, R. Salazar, Genomic classifier ColoPrint predicts recurrence in stage II colorectal cancer patients more accurately than clinical factors. Oncologist 20, 127-133 (2015).
9. A. P. Venook, D. Niedzwiecki, M. Lopatin, X. Ye, M. Lee, P. N. Friedman, W. Frankel, K. Clark-Langone, C. Millward, S. Shak, R. M. Goldberg, N. N. Mahmoud, R. S. Warren, R. L. Schilsky, M. M. Bertagnolli, Biologic determinants of tumor recurrence in stage II colon cancer: Validation study of the 12-gene recurrence score in Cancer and Leukemia Group B (CALGB) 9581. J. Clin. Oncol. 31, 1775-1781 (2013).
10. R. G. Gray, P. Quirke, K. Handley, M. Lopatin, L. Magill, F. L. Baehner, C. Beaumont, K. M. Clark-Langone, C. N. Yoshizawa, M. Lee, D. Watson, S. Shak, D. J. Kerr, Validation study of a quantitative multigene reverse transcriptase-polymerase chain reaction assay for assessment of recurrence risk in patients with stage II colon cancer. J. Clin. Oncol. 29, 4611-4619 (2011).
11. J.-X. Zhang, W. Song, Z.-H. Chen, J.-H. Wei, Y.-J. Liao, J. Lei, M. Hu, G.-Z. Chen, B. Liao, J. Lu, H.-W. Zhao, W. Chen, Y.-L. He, H.-Y. Wang, D. Xie, J.-H. Luo, Prognostic and predictive value of a microRNA signature in stage II colon cancer: A microRNA expression analysis. Lancet Oncol. 14, 1295-1306 (2013).
12. E. S. O'Connor, D. Y. Greenblatt, N. K. LoConte, R. E. Gangnon, J.-I. Liou, C. P. Heise, M. A. Smith, Adjuvant chemotherapy for stage II colon cancer with poor prognostic features. J. Clin. Oncol. 29, 3381-3388 (2011).
13. A. Figueredo, M. L. Charette, J. Maroun, M. C. Brouwers, L. Zuraw, Adjuvant therapy for stage II colon cancer: A systematic review from the Cancer Care Ontario Program in evidence-based care's gastrointestinal cancer disease site group. J. Clin. Oncol. 22, 3395-3407 (2004).
14. E. Mamounas, S. Wieand, N. Wolmark, H. D. Bear, J. N. Atkins, K. Song, J. Jones, H. Rockette, Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: Results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04). J. Clin. Oncol. 17, 1349-1355 (1999).
15. QUASAR Collaborative Group, R. Gray, J. Barnwell, C. McConkey, R. K. Hills, N. S. Williams, D. J. Kerr, Adjuvant chemotherapy versus observation in patients with colorectal cancer: A randomised study. Lancet 370, 2020-2029 (2007).
16. T. André, A. de Gramont, D. Vernerey, B. Chibaudel, F. Bonnetain, A. Tijeras-Raballand, A. Scriva, T. Hickish, J. Tabernero, J. L. Van Laethem, M. Banzi, E. Maartense, E. Shmueli, G. U. Carlsson, W. Scheithauer, D. Papamichael, M. Möehler, S. Landolfi, P. Demetter, S. Colote, C. Tournigand, C. Louvet, A. Duval, J.-F. Fléjou, A. de Gramont, Adjuvant fluorouracil, leucovorin, and oxaliplatin in stage II to III colon cancer: Updated 10-year survival and outcomes according to BRAF mutation and mismatch repair status of the MOSAIC study. J. Clin. Oncol. 33, 4176-4187 (2015).
17. G. M. Jeffery, B. E. Hickey, P. Hider, Follow-up strategies for patients treated for non-metastatic colorectal cancer. Cochrane Database Syst. Rev., CD002200 (2002).
18. A. G. Renehan, M. Egger, M. P. Saunders, S. T. O'Dwyer, Impact on survival of intensive follow up after curative resection for colorectal cancer: Systematic review and meta-analysis of randomised trials. BMJ 324, 813 (2002).
19. A. Figueredo, R. B. Rumble, J. Maroun, C. C. Earle, B. Cummings, R. McLeod, L. Zuraw, C. Zwaal; Gastrointestinal Cancer Disease Site Group of Cancer Care Ontario's Program in Evidence-based Care, Follow-up of patients with curatively resected colorectal cancer: A practice guideline. BMC Cancer 3, 26 (2003).
20. S. Pita-Fernàndez, M. Alhayek-Aí, C. González-Martín, B. López-Calviño, T. Seoane-Pillado, S. Pértega-Díaz, Intensive follow-up strategies improve outcomes in nonmetastatic colorectal cancer patients after curative surgery: A systematic review and meta-analysis. Ann. Oncol. 26, 644-656 (2015).
21. M. Chao, P. Gibbs, Caution is required before recommending routine carcinoembryonic antigen and imaging follow-up for patients with early-stage colon cancer. J. Clin. Oncol. 27, e279-e280 (2009).
22. A. B. Benson III, C. E. Desch, P. J. Flynn, C. Krause, C. L. Loprinzi, B. D. Minsky, N. J. Petrelli, D. G. Pfister, T. J. Smith, M. R. Somerfield; American Society of Clinical Oncology, 2000 update of American Society of Clinical Oncology colorectal cancer surveillance guidelines. J. Clin. Oncol. 18, 3586-3588 (2000).
23. L. D. Wood, D. W. Parsons, S. Jones, J. Lin, T. Sjöblom, R. J. Leary, D. Shen, S. M. Boca, T. Barber, J. Ptak, N. Silliman, S. Szabo, Z. Dezso, V. Ustyanksky, T. Nikolskaya, Y. Nikolsky, R. Karchin, P. A. Wilson, J. S. Kaminker, Z. Zhang, R. Croshaw, J. Willis, D. Dawson, M. Shipitsin, J. K. V. Willson, S. Sukumar, K. Polyak, B. H. Park, C. L. Pethiyagoda, P. V. K. Pant, D. G. Ballinger, A. B. Sparks, J. Hartigan, D. R. Smith, E. Suh, N. Papadopoulos, P. Buckhaults, S. D. Markowitz, G. Parmigiani, K. W. Kinzler, V. E. Velculescu, B. Vogelstein, The genomic landscapes of human breast and colorectal cancers. Science 318, 1108-1113 (2007).
24. Cancer Genome Atlas Network, Comprehensive molecular characterization of human colon and rectal cancer. Nature 487, 330-337 (2012).
25. L. A. Diaz Jr., R. T. Williams, J. Wu, I. Kinde, J. R. Hecht, J. Berlin, B. Allen, I. Bozic, J. G. Reiter, M. A. Nowak, K. W. Kinzler, K. S. Oliner, B. Vogelstein, The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature 486, 537-540 (2012).
26. C. Bettegowda, M. Sausen, R. J. Leary, I. Kinde, Y. Wang, N. Agrawal, B. R. Bartlett, H. Wang, B. Luber, R. M. Alani, E. S. Antonarakis, N. S. Azad, A. Bardelli, H. Brem, J. L. Cameron, C. C. Lee, L. A. Fecher, G. L. Gallia, P. Gibbs, D. Le, R. L. Giuntoli, M. Goggins, M. D. Hogarty, M. Holdhoff, S.-M. Hong, Y. Jiao, H. H. Juhl, J. J. Kim, G. Siravegna, D. A. Laheru, C. Lauricella, M. Lim, E. J. Lipson, S. K. N. Marie, G. J. Netto, K. S. Oliner, A. Olivi, L. Olsson, G. J. Riggins, A. Sartore-Bianchi, K. Schmidt, I.-M. Shih, S. M. Oba-Shinjo, S. Siena, D. Theodorescu, J. Tie, T. T. Harkins, S. Veronese, T.-L. Wang, J. D. Weingart, C. L. Wolfgang, L. D. Wood, D. Xing, R. H. Hruban, J. Wu, P. J. Allen, C. M. Schmidt, M. A. Choti, V. E. Velculescu, K. W. Kinzler, B. Vogelstein, N. Papadopoulos, L. A. Diaz Jr., Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci. Transl. Med. 6, 224ra24 (2014).
27. S. Misale, R. Yaeger, S. Hobor, E. Scala, M. Janakiraman, D. Liska, E. Valtorta, R. Schiavo, M. Buscarino, G. Siravegna, K. Bencardino, A. Cercek, C.-T. Chen, S. Veronese, C. Zanon, A. Sartore-Bianchi, M. Gambacorta, M. Gallicchio, E. Vakiani, V. Boscaro, E. Medico, M. Weiser, S. Siena, F. Di Nicolantonio, D. Solit, A. Bardelli, Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 486, 532-536 (2012).
28. M. P. Morelli, M. J. Overman, A. Dasari, S. M. A. Kazmi, T. Mazard, E. Vilar, V. K. Morris, M. S. Lee, D. Herron, C. Eng, J. Morris, B. K. Kee, F. Janku, F. L. Deaton, C. Garrett, D. Maru, F. Diehl, P. Angenendt, S. Kopetz, Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment. Ann. Oncol. 26, 731-736 (2015).
29. F. Diehl, K. Schmidt, M. A. Choti, K. Romans, S. Goodman, M. Li, K. Thornton, N. Agrawal, L. Sokoll, S. A. Szabo, K. W. Kinzler, B. Vogelstein, L. A. Diaz Jr., Circulating mutant DNA to assess tumor dynamics. Nat. Med. 14, 985-990 (2008).
30. J. Tie, I. Kinde, Y. Wang, H. L. Wong, J. Roebert, M. Christie, M. Tacey, R. Wong, M. Singh, C. S. Karapetis, J. Desai, B. Tran, R. L. Strausberg, L. A. Diaz Jr., N. Papadopoulos, K. W. Kinzler, B. Vogelstein, P. Gibbs, Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer. Ann. Oncol. 26, 1715-1722 (2015).
31. I. Garcia-Murillas, G. Schiavon, B. Weigelt, C. Ng, S. Hrebien, R. J. Cutts, M. Cheang, P. Osin, A. Nerurkar, I. Kozarewa, J. A. Garrido, M. Dowsett, J. S. Reis-Filho, I. E. Smith, N. C. Turner, Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer. Sci. Transl. Med. 7, 302ra133 (2015).
32. M. Sausen, J. Phallen, V. Adleff, S. Jones, R. J. Leary, M. T. Barrett, V. Anagnostou, S. Parpart-Li, D. Murphy, Q. Kay Li, C. A. Hruban, R. Scharpf, J. R. White, P. J. O'Dwyer, P. J. Allen, J. R. Eshleman, C. B. Thompson, D. S. Klimstra, D. C. Linehan, A. Maitra, R. H. Hruban, L. A. Diaz Jr., D. D. Von Hoff, J. S. Johansen, J. A. Drebin, V. E. Velculescu, Clinical implications of genomic alterations in the tumour and circulation of pancreatic cancer patients. Nat. Commun. 6, 7686 (2015).
33. I. Kinde, J. Wu, N. Papadopoulos, K. W. Kinzler, B. Vogelstein, Detection and quantification of rare mutations with massively parallel sequencing. Proc. Natl. Acad. Sci. U.S.A. 108, 9530-9535 (2011).
34. D. A. Wirtzfeld, L. Mikula, R. Gryfe, P. Ravani, E. L. Dicks, P. Parfrey, S. Gallinger, W. G. Pollett, Concordance with clinical practice guidelines for adjuvant chemotherapy in patients with stage I-III colon cancer: Experience in 2 Canadian provinces. Can. J. Surg. 52, 92-97 (2009).
35. J. B. O'Connell, M. A. Maggard, C. Y. Ko, Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J. Natl. Cancer Inst. 96, 1420-1425 (2004).
36. I. Bozic, J. G. Reiter, B. Allen, T. Antal, K. Chatterjee, P. Shah, Y. S. Moon, A. Yaqubie, N. Kelly, D. T. Le, E. J. Lipson, P. B. Chapman, L. A. Diaz Jr., B. Vogelstein, M. A. Nowak, Evolutionary dynamics of cancer in response to targeted combination therapy. Elife 2, e00747 (2013).
37. A. M. Newman, A. F. Lovejoy, D. M. Klass, D. M. Kurtz, J. J. Chabon, F. Scherer, H. Stehr, C. L. Liu, S. V. Bratman, C. Say, L. Zhou, J. N. Carter, R. B. West, G. W. Sledge Jr., J. B. Shrager, B. W. Loo Jr., J. W. Neal, H. A. Wakelee, M. Diehn, A. A. Alizadeh, Integrated digital error suppression for improved detection of circulating tumor DNA. Nat. Biotechnol. 34, 547-555 (2016).
38. J. Shia, Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome. Part I. The utility of immunohistochemistry. J. Mol. Diagn. 10, 293-300 (2008).
39. I. Kinde, C. Bettegowda, Y. Wang, J. Wu, N. Agrawal, I.-M. Shih, R. Kurman, F. Dao, D. A. Levine, R. Giuntoli, R. Roden, J. R. Eshleman, J. P. Carvalho, S. K. N. Marie, N. Papadopoulos, K. W. Kinzler, B. Vogelstein, L. A. Diaz Jr., Evaluation of DNA from the Papanicolaou test to detect ovarian and endometrial cancers. Sci. Transl. Med. 5, 167ra4 (2013).
40. P. J. Heagerty, T. Lumley, M. S. Pepe, Time-dependent ROC curves for censored survival data and a diagnostic marker. Biometrics 56, 337-344 (2000).